Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”), along with subsidiary Clene Nanomedicine, is announcing the publication of a peer-reviewed article describing brain target engagement by CNM-Au8(R), the company’s lead drug candidate. Coauthored by physician scientists from the University of Texas Southwestern Medical Center and Clene, the paper is titled “Evidence of Brain Target Engagement in Parkinson’s Disease and Multiple Sclerosis by the Investigational Nanomedicine, CNM-Au8, in the REPAIR Phase 2 Clinical Trials” and was published in the “Journal of Nanobiotechnology.” The article outlines results from the successful phase 2 REPAIR clinical studies designed to evaluate and measure changes in brain-energy metabolites in multiple sclerosis and Parkinson’s disease when treated with CNM-Au8. The data indicated a significant increase in brain NAD+/NADH ratio from baseline, the studies’ primary endpoint, following 12 weeks of daily oral dosing of CNM-Au8 with the study concluding that CNM-Au8 treatment resulted in favorable modulation of additional brain energy metabolites that have been shown to be dysregulated in neurodegenerative diseases. “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant,” said Clene head of medical Dr. Benjamin Greenberg in the press release. “Other groups have shown significant deficits in brain-energy metabolites associated with neurodegenerative disease. For example, brain levels of NAD are deficient in Parkinson’s disease, and deficits in brain ATP levels correlate with the Expanded Disability Status clinical scale for multiple sclerosis. Even in healthy aging, the human brain’s NAD+/NADH decreases at a rate of loss of approximately half a percent per decade. Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”
To view the full article, visit https://ibn.fm/gwQA8
To view the full press release, visit https://ibn.fm/SA476
About Clene Inc.
Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
